Agalsidase beta Completed Phase 4 Trials for Fabry's Disease

IndicationsStatusPurposePhase
CompletedNot Available4
clinicaltrials.gov IdentifierTitleDrugs
NCT00233870A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.